San Francisco, United States
Solvemed, founded in 2019, is spearheading innovation in the intersection of AI, Medical Devices, and Machine Learning. Their flagship product, the PuRe Pupillometer, transforms any iPhone into a FDA-certified medical device capable of conducting comprehensive, automated pupil light reflex assessments.
The development is especially impactful for neuro-critical care, where the PuRe Pupillometer provides real-time, objective metrics essential for evaluating and trending neurological functions, epitomized by the PuRe score, a reliable 0–5 scale unaffected by ambient light.
Solvemed’s open-source approach to the PuRe formula underlines its commitment to advancing clinical research. The US-based startup received a substantial £3.20M Seed Round funding in October 2022 from distinguished investors like Apex Ventures, Atmos Ventures, Preface Ventures, Sunfish Partners, Techni Ventures, and Tensor Ventures, validating its disruptive potential in medical technology.
